Letter to the editor

DOI: 10.4244/EIJ-D-24-00974

LETTER: An update on changes to the design of the ODIN trial

Sigrid Sandner1,2, MD, MSCE; Björn Redfors3,4,5, MD, PhD; Marc Ruel6, MD, MPH; Mario Gaudino2, MD, PhD, MSCE

We recently published, in EuroIntervention Volume 20, Number 5, the rationale and design of the One-Month DAPT in CABG Patients (ODIN) trial (ClinicalTrials.gov: NCT05997693)1. ODIN is designed to address a critical gap in knowledge: whether short-term dual antiplatelet therapy (DAPT) with low-dose aspirin and ticagrelor is more effective than aspirin alone to reduce the risk of ischemic events and graft failure after coronary artery bypass graft (CABG) surgery in patients with chronic coronary syndromes while minimising the risk of bleeding associated with longer DAPT durations. The trial was initially conceived as a prospective, randomised, double-blind, placebo-controlled, international, multicentre study.

Despite our best efforts over the past year, we have encountered significant challenges in securing a suitable placebo for ticagrelor. These challenges have been multifaceted and have included difficulties identifying a manufacturer, the prohibitive cost associated with placebo production, and the lengthy time frames required for manufacturing and regulatory approval. Ultimately, these obstacles have made it unfeasible to conduct the study as a placebo-controlled trial as initially planned. This experience is not unique to ODIN; the challenges faced by investigator-initiated drug...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 6
Mar 17, 2025
Volume 21 Number 6
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-22-00022 Aug 19, 2022
One-month DAPT after acute coronary syndrome: too short or not too short?
Capranzano P
free

10.4244/EIJV13I16A303 Mar 20, 2018
DAPT rules
Bittl J et al
free
Trending articles
95.95

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
76.55

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
63

Image – Interventional flashlight

10.4244/EIJ-D-22-00074 Jun 3, 2022
Transcatheter aortic valve repair for aortic regurgitation with the Cusper device
Feld Y et al
free
58.2

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
49.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
49.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
31.1

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
30.4

Clinical Research

10.4244/EIJ-D-21-00363 Jan 28, 2022
Membranous septum morphology and risk of conduction abnormalities after transcatheter aortic valve implantation
Jørgensen T et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved